Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: Independent favorable prognostic factor within NPM1 mutated patients

Annals of Hematology

Volumn 91, Issue 7, 2012, Pages 1051-1063

  Dufour, Annika ^a   Schneider, Friederike ^a   Hoster, Eva ^a   Benthaus, Tobias ^a   Ksienzyk, Bianka ^a   Schneider, Stephanie ^a   Kakadia, Purvi M ^a   Sauerland, Maria Cristina ^c   Berdel, Wolfgang E ^c   Büchner, Thomas ^c   Wörmann, Bernhard ^d   Braess, Jan ^e   Subklewe, Marion ^a   Hiddemann, Wolfgang ^a,b   Bohlander, Stefan K ^a,b   Spiekermann, Karsten ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d KLINIKUM BRAUNSCHWEIG   (Germany)

^e Barmherzige Brüder Hospital   (Germany)

Author keywords

Acute myeloid leukemia; Monoallelic CEBPA mutations; Normal karyotype; NPM1 mutation

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; MITOXANTRONE; MOLECULAR MARKER; NUCLEOPHOSMIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; GENOTYPE; HAZARD RATIO; HUMAN; KARYOTYPE; MALE; MONOALLELIC GENE MUTATION; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CCAAT-ENHANCER-BINDING PROTEINS; EPISTASIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84862762733     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1423-4     Document Type: Article

References (47)

1. DG Tenen R Hromas JD Licht DE Zhang 1997 Transcription factors, normal myeloid development, and leukemia Blood 90 2 489 519 9226149 1:CAS:528:DyaK2sXksF2jsLk%3D
2. DE Zhang P Zhang ND Wang CJ Hetherington GJ Darlington DG Tenen 1997 Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice Proc Natl Acad Sci U S A 94 2 569 574 9012825 10.1073/pnas.94.2.569 1:CAS:528: DyaK2sXnslGjtg%3D%3D
3. P Zhang J Iwasaki-Arai H Iwasaki ML Fenyus T Dayaram BM Owens H Shigematsu E Levantini CS Huettner JA Lekstrom-Himes K Akashi DG Tenen 2004 Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha Immunity 21 6 853 863 15589173 10.1016/j.immuni.2004.11.006 1:CAS:528:DC%2BD2MXjvFGjtQ%3D%3D
4. M Bienz M Ludwig EO Leibundgut BU Mueller D Ratschiller M Solenthaler MF Fey T Pabst 2005 Risk assessment in patients with acute myeloid leukemia and a normal karyotype Clin Cancer Res 11 4 1416 1424 15746041 10.1158/1078-0432.CCR- 04-1552 1:CAS:528:DC%2BD2MXhvVSrsLo%3D
5. A Dufour F Schneider KH Metzeler E Hoster S Schneider E Zellmeier T Benthaus MC Sauerland WE Berdel T Buchner B Wormann J Braess W Hiddemann SK Bohlander K Spiekermann 2009 Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome J Clin Oncol 28 4 570 577 20038735 10.1200/JCO.2008.21.6010
6. S Frohling RF Schlenk I Stolze J Bihlmayr A Benner S Kreitmeier K Tobis H Dohner K Dohner 2004 CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations J Clin Oncol 22 4 624 633 14726504 10.1200/JCO.2004.06.060
7. T Pabst BU Mueller P Zhang HS Radomska S Narravula S Schnittger G Behre W Hiddemann DG Tenen 2001 Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia Nat Genet 27 3 263 270 11242107 10.1038/85820 1:CAS:528:DC%2BD3MXhslOjs78%3D
8. AF Gombart WK Hofmann S Kawano S Takeuchi U Krug SH Kwok RJ Larsen H Asou CW Miller D Hoelzer HP Koeffler 2002 Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias Blood 99 4 1332 1340 11830484 10.1182/blood.V99.4.1332 1:CAS:528:DC%2BD38XhtlWqtro%3D
9. H Asou AF Gombart S Takeuchi H Tanaka M Tanioka H Matsui A Kimura T Inaba HP Koeffler 2003 Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene Genes Chromosomes Cancer 36 2 167 174 12508245 10.1002/gcc.10161 1:CAS:528:DC%2BD3sXhtlKmt7s%3D
10. CL Green KK Koo RK Hills AK Burnett DC Linch RE Gale 2010 Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations J Clin Oncol 28 16 2739 2747 20439648 10.1200/JCO.2009.26.2501 1:CAS:528:DC%2BC3cXoslyktbw%3D
11. T Pabst M Eyholzer J Fos BU Mueller 2009 Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis Br J Cancer 100 8 1343 1346 19277035 10.1038/sj.bjc.6604977 1:CAS:528:DC%2BD1MXksF2gt7g%3D
12. E Taskesen L Bullinger A Corbacioglu M Sanders CA Erpelinck BJ Wouters S van der Poel-vandeLuytgaarde F Damm J Krauter A Ganser RF Schlenk B Lowenberg R Delwel H Dohner PJ Valk K Dohner 2011 Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity Blood 117 8 2469 2475 21177436 10.1182/blood-2010-09-307280 1:CAS:528:DC%2BC3MXjsVWnsbo%3D
13. BJ Wouters B Lowenberg CA Erpelinck-Verschueren WL van Putten PJ Valk R Delwel 2009 Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood 113 13 3088 3091 19171880 10.1182/blood-2008-09-179895 1:CAS:528:DC%2BD1MXktFWnt74%3D
14. B van Waalwijk S van Doorn-Khosrovani C Erpelinck J Meijer S van Oosterhoud WL van Putten PJ Valk H Berna Beverloo DG Tenen B Lowenberg R Delwel 2003 Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML Hematol J 4 1 31 40 10.1038/sj.thj.6200216
15. LI Lin CY Chen DT Lin W Tsay JL Tang YC Yeh HL Shen FH Su M Yao SY Huang HF Tien 2005 Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells Clin Cancer Res 11 4 1372 1379 15746035 10.1158/1078-0432.CCR-04-1816 1:CAS:528:DC%2BD2MXhvVSrs7Y%3D
16. O Bereshchenko E Mancini S Moore D Bilbao R Mansson S Luc A Grover SE Jacobsen D Bryder C Nerlov 2009 Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML Cancer Cell 16 5 390 400 19878871 10.1016/j.ccr.2009.09.036 1:CAS:528:DC%2BD1MXhsFKltb3M
17. N Kato J Kitaura N Doki Y Komeno N Watanabe-Okochi K Togami F Nakahara T Oki Y Enomoto Y Fukuchi H Nakajima Y Harada H Harada T Kitamura 2011 Two types of C/EBP{alpha} mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models Blood 117 1 221 233 20884804 10.1182/blood-2010-02-270181 1:CAS:528:DC%2BC3MXhtFGrtr0%3D
18. P Kirstetter MB Schuster O Bereshchenko S Moore H Dvinge E Kurz K Theilgaard-Monch R Mansson TA Pedersen T Pabst E Schrock BT Porse SE Jacobsen P Bertone DG Tenen C Nerlov 2008 Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells Cancer Cell 13 4 299 310 18394553 10.1016/j.ccr.2008. 02.008 1:CAS:528:DC%2BD1cXkslSjtro%3D
19. TC Somervaille ML Cleary 2009 Preview. Mutant CEBPA: priming stem cells for myeloid leukemogenesis. Cell Stem Cell 5 5 453 454 19896432 10.1016/j.stem.2009.10.008 1:CAS:528:DC%2BD1MXhsFKltLrL
20. K Dohner RF Schlenk M Habdank C Scholl FG Rucker A Corbacioglu L Bullinger S Frohling H Dohner 2005 Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 106 12 3740 3746 16051734 10.1182/blood-2005-05-2164
21. B Falini C Mecucci E Tiacci M Alcalay R Rosati L Pasqualucci R La Starza D Diverio E Colombo A Santucci B Bigerna R Pacini A Pucciarini A Liso M Vignetti P Fazi N Meani V Pettirossi G Saglio F Mandelli F Lo-Coco PG Pelicci MF Martelli 2005 Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype N Engl J Med 352 3 254 266 15659725 10.1056/NEJMoa041974 1:CAS:528:DC%2BD2MXmslShug%3D%3D
22. S Schnittger C Schoch W Kern C Mecucci C Tschulik MF Martelli T Haferlach W Hiddemann B Falini 2005 Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 106 12 3733 3739 16076867 10.1182/blood-2005-06-2248 1:CAS:528: DC%2BD2MXht12ksbjJ
23. RF Schlenk K Dohner J Krauter S Frohling A Corbacioglu L Bullinger M Habdank D Spath M Morgan A Benner B Schlegelberger G Heil A Ganser H Dohner 2008 Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 18 1909 1918 18450602 10.1056/NEJMoa074306 1:CAS:528:DC%2BD1cXlt1Ggu70%3D
24. RG Verhaak CS Goudswaard W van Putten MA Bijl MA Sanders W Hugens AG Uitterlinden CA Erpelinck R Delwel B Lowenberg PJ Valk 2005 Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Blood 106 12 3747 3754 16109776 10.1182/blood-2005-05-2168 1:CAS:528:DC%2BD2MXht12ksbnM
25. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363 (25):2424-2433
26. ER Mardis L Ding DJ Dooling DE Larson MD McLellan K Chen DC Koboldt RS Fulton KD Delehaunty SD McGrath LA Fulton DP Locke VJ Magrini RM Abbott TL Vickery JS Reed JS Robinson T Wylie SM Smith L Carmichael JM Eldred CC Harris J Walker JB Peck F Du AF Dukes GE Sanderson AM Brummett E Clark JF McMichael RJ Meyer JK Schindler CS Pohl JW Wallis X Shi L Lin H Schmidt Y Tang C Haipek ME Wiechert JV Ivy J Kalicki G Elliott RE Ries JE Payton P Westervelt MH Tomasson MA Watson J Baty S Heath WD Shannon R Nagarajan DC Link MJ Walter TA Graubert JF DiPersio RK Wilson TJ Ley 2009 Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 361 11 1058 1066 19657110 10.1056/NEJMoa0903840 1:CAS:528:DC%2BD1MXhtFaltLvL
27. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, Liang WX, Mi JQ, Song HD, Li KQ, Chen Z, Chen SJ (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43 (4):309-315
28. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Lowenberg B, Valk PJ (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116 (12):2122-2126
29. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE (2010) The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116 (15):2779-2782
30. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28 (14):2348-2355
31. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K, Horst HA, Germing U, Dohner H, Dohner K (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28 (22):3636-3643
32. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, Yun H, Gohring G, Schlegelberger B, Hoelzer D, Lubbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M (2010) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29 (21):2889-2896
33. RG Verhaak BJ Wouters CA Erpelinck S Abbas HB Beverloo S Lugthart B Lowenberg R Delwel PJ Valk 2009 Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling Haematologica 94 1 131 134 18838472 10.3324/haematol.13299
34. T Buchner WE Berdel C Schoch T Haferlach HL Serve J Kienast S Schnittger W Kern J Tchinda A Reichle E Lengfelder P Staib WD Ludwig C Aul H Eimermacher L Balleisen MC Sauerland A Heinecke B Wormann W Hiddemann 2006 Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia J Clin Oncol 24 16 2480 2489 16735702 10.1200/JCO.2005.04.5013
35. T Benthaus F Schneider G Mellert E Zellmeier S Schneider PM Kakadia W Hiddemann SK Bohlander M Feuring-Buske J Braess K Spiekermann A Dufour 2008 Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia Br J Haematol 143 2 230 239 18752591 10.1111/j.1365-2141.2008.07328.x 1:CAS:528:DC%2BD1cXhtlWisb%2FI
36. C Papadaki A Dufour M Seibl S Schneider SK Bohlander E Zellmeier G Mellert W Hiddemann K Spiekermann 2009 Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor Br J Haematol 144 4 517 523 19055671 10.1111/j.1365-2141.2008.07488.x 1:CAS:528:DC%2BD1MXjtlehtrw%3D
37. S Schnittger C Schoch M Dugas W Kern P Staib C Wuchter H Loffler CM Sauerland H Serve T Buchner T Haferlach W Hiddemann 2002 Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 1 59 66 12070009 10.1182/blood.V100.1.59 1:CAS:528:DC%2BD38XltF2rs7g%3D
38. U Bacher C Haferlach W Kern T Haferlach S Schnittger 2008 Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients Blood 111 5 2527 2537 17965322 10.1182/blood-2007-05-091215 1:CAS:528:DC%2BD1cXivFaktrc%3D
39. S Schnittger U Kinkelin C Schoch A Heinecke D Haase T Haferlach T Buchner B Wormann W Hiddemann F Griesinger 2000 Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML Leukemia 14 5 796 804 10803509 10.1038/sj.leu.2401773 1:CAS:528:DC%2BD3cXjsFCqt7o%3D
40. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel MC, Reifenberger G (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119 (4):501-507
41. Markova J, Michkova P, Burckova K, Brezinova J, Michalova K, Dohnalova A, Maaloufova JS, Soukup P, Vitek A, Cetkovsky P, Schwarz J (2010) Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol 88 (2):128-135
42. C Thiede S Koch E Creutzig C Steudel T Illmer M Schaich G Ehninger 2006 Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood 107 10 4011 4020 16455956 10.1182/blood-2005-08-3167 1:CAS:528:DC%2BD28XkvFWhu7c%3D
43. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115 (3):453-474
44. RE Gale C Green C Allen AJ Mead AK Burnett RK Hills DC Linch 2008 The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 111 5 2776 2784 17957027 10.1182/blood-2007-08- 109090 1:CAS:528:DC%2BD1cXivFaktbY%3D
45. PD Kottaridis RE Gale ME Frew G Harrison SE Langabeer AA Belton H Walker K Wheatley DT Bowen AK Burnett AH Goldstone DC Linch 2001 The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 6 1752 1759 11535508 10.1182/blood.V98.6.1752 1:CAS:528:DC%2BD3MXntFWgsbg%3D
46. LY Shih CF Huang JH Wu TL Lin P Dunn PN Wang MC Kuo CL Lai HC Hsu 2002 Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse Blood 100 7 2387 2392 12239146 10.1182/blood-2002-01-0195 1:CAS:528:DC%2BD38XnvVGis7Y%3D
47. A Andersson B Johansson C Lassen F Mitelman R Billstrom T Fioretos 2004 Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients Eur J Haematol 72 5 307 313 15059064 10.1111/j.1600-0609.2004.00225.x 1:CAS:528:DC%2BD2cXkt1Kgu74%3D